Update on Peptic Ulcers in the Pediatric Age by Graziella Guariso & Marco Gasparetto
Hindawi Publishing Corporation
Ulcers
Volume 2012, Article ID 896509, 9 pages
doi:10.1155/2012/896509
Review Article
Updateon PepticUlcersinthePediatric Age
GraziellaGuarisoandMarco Gasparetto
Unit of Gastroenterology, Digestive Endoscopy, Hepatology, and Care of the Child with Liver Transplantation,
Department of Woman and Child Health, University Hospital of Padova, Via Giustiniani 2, 35128 Padova, Italy
Correspondence should be addressed to Marco Gasparetto, markgasp@gmail.com
Received 11 August 2012; Accepted 4 September 2012
Academic Editor: Joachim Labenz
Copyright © 2012 G. Guariso and M. Gasparetto. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Background. Peptic ulcer disease (PUD) in children is reported worldwide, although it is relatively rare as compared with adults.
Helicobacterpylori(HP)infectionisacommoncauseofPUDinthepediatricage.Otherriskfactorsincludetheuseofnonsteroidal
anti-inﬂammatory agents (NSAIDs), steroids, immunosuppressive drugs, and stressful events. Aim. To critically review the
evidence on epidemiology, diagnostic management, and available treatments for PUD in the pediatric age.M e t h o d s .AM E D L I N E
search was performed indicating keywords as “Peptic Ulcer Disease,” “Epidemiology,” “Pediatric,” “Helicobacter pylori,” “Gastric
ulcer,” “Bulbar Ulcer,” and “Upper Gastrointestinal Bleeding.” A selection of clinical trials, systematic reviews, and meta-analyses
within the time period 2002–2012 was performed. Results. PUD in children is reported worldwide with an estimated frequency
of 8.1% in Europe and of 17.4% in the US. When the underlying cause of PUD is addressed, the prognosis is excellent. Standard
triple therapy, bismuth-based quadruple therapy, and the sequential therapy represent the current recommended treatments for
HP related ulcers. NSAIDs related ulcers are treated by stopping the causative medications and by administration of proton-pump
inhibitors or antisecretory drugs. Conclusions. PUD still represents a major concern in the paediatric age. A careful diﬀerential
diagnosis and an adequate treatment constitute an excellent prognosis.
1.Introduction
Peptic ulcers are discontinuities of the gastric or duodenal
mucosa with penetration to the muscularis mucosae and
exposure of the submucosa [1, 2].
Primitive ulcers are caused by alterations of the gastric
function (i.e., increased HCl production and pepsin func-
tion); they are mainly single lesions and are usually found
at the small gastric curve and at the antrum.
Secondary ulcers, on the contrary, are caused by extra-
gastric pathogenic events, that is, stress or drugs. They can
be multiple and can have a spread localization within the
stomach.
More than 20% of patients have a family history of
duodenal ulcers. In up to one third of patients with duodenal
ulcers, basal acid output (BAO) and maximal acid output
are increased. A study by Schubert and Peura [3] attested
that individuals are at especially high risk those with a basal
acid production (BAP) greater than 15mEq/h. In addition to
the increased gastric and duodenal acidity observed in some
patients with duodenal ulcers, accelerated gastric emptying
is also often present.
A common cause of peptic ulcers in the pediatric age
is Helicobacter pylori (HP) infection [4–6], though the use
of nonsteroidal anti-inﬂammatory agents (NSAIDs), like
aspirin and ibuprofen, represents a signiﬁcant cause of ulcers
as well [7].
Other treatments comprehending steroids and antineo-
plastic and immunosuppressive drugs can be causative of
peptic ulcers. A reduction of the protective eﬀect of pros-
taglandins on gastric mucosa is considered to be the main
pathogenic mechanism.
Other stressful events (i.e., shock, sepsis, burnings, major
trauma, intracranial hypertension, surgical procedures, and
chronic diseases) can provoke acute gastric ulcers, also in
the pediatric age [8]. Lesions generally appear 3–6 days after
the event and the main related symptoms are bleeding and2 Ulcers
abdominal pain. Most of times, multiple lesions involving
any part of the stomach are observed.
Cushing ulcers are associated with a brain tumor or
injury; they are typically single, deep ulcers located in the
duodenum or stomach that are prone to perforation.
Stress and spicy foods do not cause ulcers, but can
exacerbate existing ones. Obesity has been shown to have
an association with PUD, and patients should be counseled
regarding beneﬁts of weight loss.
Children presenting serious medical conditions may
develop peptic ulcers as a secondary condition. Neoplastic
ulcers are instead related to development of lymphomas.
Hypersecretory states that may uncommonly cause
peptic ulcer disease (PUD) include gastrinoma (Zollinger-
Ellison syndrome), multiple endocrine neoplasia type I
(MEN-I), antral G-cell hyperplasia, systemic mastocytosis,
basophilic leukemias, cystic ﬁbrosis, short bowel syndrome,
and hyperparathyroidism.
The most signiﬁcant ulcer related symptoms involve dull
stomach ache or pain, intermittent abdominal discomfort
(typically occurring several hours after a meal or in an empty
stomach, often being relieved by eating), gas and bloating,
nausea and, less commonly, vomiting [9].
Gastric and duodenal ulcers cannot be diﬀerentiated
based on history alone, although some ﬁndings may be
suggestive. Epigastric pain is the most common symptom of
both gastric and duodenal ulcers and is characterized by a
gnawing or burning sensation occurring shortly after meals
with gastric ulcer and 2-3 hours afterward with duodenal
ulcer [9].
Alarm symptoms supporting the suspect of GI bleeding
or ulcer perforation involve sudden, sharp abdominal pain,
black or bloody stools, and bloody or coﬀee-like vomits.
Other alarm features which warrant prompt gastroen-
terology referral include anemia, early satiety, unexplained
weight loss, progressive dysphagia or odynophagia, and
family history of GI cancer [9].
Diagnostic examinations include urease test, stool tests
for HP detection, and upper-gastrointestinal (GI) tract
endoscopy [9].
In most patients with uncomplicated PUD, routine lab-
oratory tests are usually unhelpful; only a combined evalua-
tionofserumpepsinogensA(PGA)andC(PGC),gastrin-17
(G17), and anti-HP antibodies (GastroPanel) [10]h a sb e e n
proposed as a useful blood test to investigate HP-associated
gastric mucosal inﬂammation.
Plasma contains two main gastrin isoforms: gastrin 34
(G34, large gastrin) and gastrin 17 (G17, small gastrin).
G17 accounts for about 95% of antral gastrin, while G34
accounts for about 60% of duodenal gastrin. When the
gastric mucosa is inﬂamed, its secretory function may be
signiﬁcantlyaltered.HPmayenhancegastrinreleasethrough
bacterial urease catalysing the production of ammonia
which acts directly on gastrin cells, as well as through the
proinﬂammatory cytokines IL-8, IL-2, and TNF-α which
enhance gastrin secretion [10].
Sinceendoscopyisnotrecommendedasaﬁrstdiagnostic
approach for children with abdominal pain without alarm
symptoms and since it cannot be performed in every centre,
GastroPanel appears to be useful as a non invasive biochem-
ical test, to support the decision to perform or not upper-
gastrointestinal endoscopy, thus to optimize the healthcare
resources. The serum determination of PGA, PGC, and of
their derived index, PGA/PGC, associated with G17 and
anti-HP antibodies allows a more accurate characterization
of the aetiology (whether or not associated with HP) and
topography (antral and/or corpus predominant) of gastritis
[10].
Negativetestresultsshouldallowpediatricianstoreason-
ably rule out the presence of major gastroduodenal diseases
and therefore to avoid endoscopy [10].
Rapid urease tests are considered the test of choice to
detect HP; among noninvasive tests, fecal antigen testing is
more accurate than antibody testing [11].
Upper-GI endoscopy is the preferred diagnostic test for
the evaluation of patients with suspected PUD, consenting
to detect the presence and degree of active bleeding, and
to attempt hemostasis by direct measures, if required. A
secondary role is currently represented by the upper-GI-tract
X-ray [9].
The 2011 Evidence-based Guidelines from ESPGHAN
and NASPGHAN for HP infection in children are based
on a systematic revision of the literature referring to the
time period 2000–2007 [12].Anevidencegradewasassigned
according to the classiﬁcation system of the Oxford Centre
for Evidence Based Medicine, and 490 out of 2042 papers
were included.
Within the pediatric population, HP related gastroin-
testinal symptoms are generally aspeciﬁc; as a consequence
the primary goal of clinical investigation of gastrointesti-
nal symptoms is to determine the underlying cause of
the symptoms and not solely the presence of H. pylori
infection. Diagnostic testing for H. pylori infection is not
recommended in children with functional abdominal pain,
whereas it can be indicated in symptomatic children with
ﬁrst grade relatives aﬀected by gastric cancer, as well as in
those children with refractory iron-deﬁcient anaemia once
the other possible diﬀerential diagnoses have been excluded.
There is no suﬃcient evidence attesting any correlation
between HP and otitis media, upper respiratory ways
infections, periodontal diseases, food allergies, idiopathic
thrombocytopenic purpura, and short stature [12].
Sensibility is of 75%–100% for urease rapid tests and of
66%–100% for histopatologic HP detection.
13C-urea breath test (UBT) has high sensibility and
speciﬁcity, thus representing a reliable noninvasive test to
detect the success of HP eradication. A false negative can be
determined by increases in gastric pH which diminish urease
activity. False positives can be observed when the marker
is degraded by intestinal ﬂora (especially in children aging
< 6 years) or when low distribution volumes determine a
diminishedCO2 productionrate.Sourcesofureaserapidtest
variability include age, marker type and dosage, meal type,
pretest fasting, detection timing, type of analysis, and cut-oﬀ
levels [12].
HP faecal antigen detection is a non invasive test which
can be reliable to determine the success of HP eradication.
Detection techniques on faecal antigen include monoclonalUlcers 3
and polyclonal EIA as well as immune-chromatographic
tests. Advantages of this technique are that it is not age-
dependant, it is more easy to be performed on children, and
less expensive. Moreover, anti-HP antibodies are resistant to
degradation [12].
Thedetectionofanti-HPantibodies(IgG,IgA)onblood,
serum, urines, and saliva is not demonstrated to be a reliable
test for clinical purposes [12].
HP culture has a low sensibility, whereas speciﬁcity is of
100%.
As a summary about HP gastritis diagnosis according to
the current available evidences, it is recommended that the
initial diagnosis of HP infection be based on either positive
histopathology and positive rapid urease test or a positive
culture. The following combined ﬁndings are required [12]:
(i) histopathology + urease rapid test,
(ii) invasive test + noninvasive test,
(iii) HP culture alone.
In order to correctly perform invasive and non invasive
tests for HP detection, the following treatment suspensions
are required [12]:
(i) proton pump inhibitors (PPIs) for at least 2 weeks,
(ii) antibiotics for at least 4 weeks.
The Forrest classiﬁcation describes four types of peptic
ulcers, based on the endoscopic characteristics of the associ-
ated upper gastrointestinal hemorrhage [13] as follows:
(i) Forrest Ia: spurting arterial bleeding;
(ii) Forrest Ib: oozing arterial hemorrhage;
(iii) Forrest IIa: large nonbleeding visible vessels;
(iv) Forrest IIb: adherent clot;
(v) Forrest IIc: hematin on ulcer base;
(vi) Forrest III: lesions without signs of recent hemor-
rhage.
Benign ulcers are endoscopically characterized by mild
dimensions, oval or roundish shape, and a whitish-grey base,
consisting in covering ﬁbrin and granulation tissue. Borders
arethinandplane.Abasalvasecanbedetectedandrepresent
asourceofhemorrhage.Gastricplicaeareusuallyconverging
to the ulcer.
Malignant ulcers generally present an irregular base,
with necrotic base covered by ﬁbrin. However, histological
examination only can diﬀerentiate the two ulcer types.
2. Aimand Methods
This paper is conceived to critically review evidence on epi-
demiology,diagnosticmanagement,andavailabletreatments
for PUD in the pediatric age. A MEDLINE search was per-
formed indicating key-words as “Peptic Ulcer Disease,” “Epi-
demiology,”“Pediatric,”“Helicobacterpylori,”“Gastriculcer,”
and “Bulbar Ulcer.” A selection of relevant English-language
clinical trials, systematic reviews, and meta-analyses within
the last ten years (time period 2002–2012) were performed.
Previousreferencesandcasereportswerealsoincludedwhen
basically supporting the ﬁrst selection. PubMed, Cochrane
Library, Trip Database, Ovid Medicine, Medscape Reference,
and Up To Date were used as referral databases. Jadad Scale
(score 0 to 5) was used as a predetermined strategy of
inclusion for clinical trials.
2.1. Epidemiology of Peptic Ulcer Disease Worldwide in the
Pediatric Population. PUD in children is reported worldwide
(Table 1), although being relatively rare as compared with
adults [14].
Solid data attesting the frequency of PUD during child-
hood in Europe have recently been described by a European
multicenter study [15] by which the role of known risk
factors within the studied population was also analyzed.
Although limited by the short-time duration and the hetero-
geneityofthe694childrenincludedthroughout19European
centres, this study shows a frequency of 8.1% of ulcers
and/or erosions in children, occurring mainly in the second
decadeoflife.HPinfectionandgastrotoxicmedicationswere
less frequently implicated than expected. More than one
risk factor was detected in 57% of the children with PUD:
HP infection was present in 27% of these children, where
NSAIDs were used in 14%, H2-blockers in 10%, antibiotics
in10%,steroidsin9%,immunesuppressivedrugsin9%,and
proton-pump inhibitors in 9% of the children. No risk fac-
torswereobservedin43%oftheenrolledchildren.Themain
indications for endoscopy were epigastric or abdominal pain
and suspicion of gastroesophageal reﬂux disease. Epigastric
tenderness, hematemesis, melena, and weight stagnation
were signiﬁcantly associated with ulcers/erosions, whereas
sex, HP infection, and socioeconomic and lifestyle factors
were equally distributed.
As regards the US, an epidemiologic study by Brown
et al. [16] aimed to determine the incidence of peptic
ulcer bleeding in pediatric patients, analyzing a hospital
inpatient database and an insurance claims database. Using
datafromtheinpatientdatabase,thetotalnumberofcasesof
hospitalization of pediatric patients for PUD bleeding in the
US in 2008 was estimated to be between 378 and 652. This
translated to an incidence of 0.5 to 0.9/100.000 individuals
in the pediatric population. Using data from the insurance
claims database, the incidence of PUB was estimated to be
4.4/100.000 individuals. Overall, 17.4% of insured pediatric
patients diagnosed as having any upper gastrointestinal
ulcer in 2008 were reported to have developed PUB. In
conclusion, the estimated incidence of PUB in the US
pediatric population in 2008 ranged from 0.5 to 4.4/100.000
individuals.
HP infection currently represents the main cause of pep-
tic ulcer in children, inﬂuencing diagnostic and treatment
procedures [8–16, 19, 20]. HP is mainly acquired in child-
hood and is particularly frequent in developing countries
[21].
The evidence for a vertical HP transmission is described
in the review by S´ ykora and Rowland, which analyzes the
main studies about HP infection between April 2010 and4 Ulcers
Table 1
Author/yr/country Study methods
Number of
children
examined
PUD PUB HP infection NSAID use
Kalach et al. [15]
2010; Europe
Multicenter,
prospective 694 56/694 (8%) n.d.a. 15/56 (27%) 8/56 (14%)
Brown et al. [16]
2012; US
Multicenter
(on national
registries),
retrospective
29.3 million 7280 1267 (17.4% of
PUD) n.d.a. n.d.a.
Shu-Ching et al.
[14] 2009; Taiwan
Monocenter,
retrospective, and
prospective
1234
67 (5.4%)
gastric 27 (40.3%)
duodenal 40 (59.7%)
43 (64.2% of PUD) 32 (47.7%) 11 (16.5%)
Egbaria et al. [17]
2008; Israel
Monocenter,
retrospective 751
169 (22.5%)
(i) ulcers 51 (6.8%),
erosions 118 (15.7%);
(ii) gastric 124 (73.3%),
duodenal 58 (34.3%)
4 (2.4% of PUD) 112 (66.3%) 34 (20.1%)
El Mouzan and
abdullah [18]
2004; Saudi Arabia
Monocenter,
retrospective, and
prospective
521
24 (5%)
gastric 4 (17%),
duodenal 20 (92%)
5 (21% of PUD) 13/15 (87%) nda
yr:year;PUD:pepticulcerdisease;PUB:pepticulcerbleeding;HP:Helicobacterpylori;NSAID:nonsteroidalanti-inﬂammatorydrugs;n.d.a.:nodataavailable.
March 2011 [22]. HP infection was associated with chronic
gastritis in all infected children, but only a subgroup of them
developed PUD [22]. The discovery of a potential role for
jhp0562,thegenewhichencodesforthecellenvelopeprotein
glycosyltransferase, in the progression to PUD is also a key
stepindistinguishingchildrenatriskofPUDfromthosewho
are not, and so determining those who require treatment to
eradicate HP.
As there are no well-established criteria leading directly
to diagnosis, the authors conclude that pediatricians should
include HP infection and PUD in the diﬀerential diagnosis
list when evaluating children with abdominal pain, failure to
thrive, and upper gastrointestinal system bleeding [22].
AT u r k i s hs t u d yb yU ˘ gras ¸ and Pehlivano˘ glu detected
PUD in 13.2% of children who underwent endoscopic
examination. In the studied population, peptic ulcers were
mostlygastricandHPpositive,andmostofthechildrenwere
admitted due to abdominal pain [21].
Unfortunately, high levels of HP treatment failure con-
tinue to be reported, and there remains an urgent need for
more eﬀective HP eradication regimes for children [22].
Moreover, the rise in non-HP-associated ulcers and
erosions continues to be reported with no apparent risk
factors for these ulcers identiﬁed to date [22].
Although the prevalence of NSAID gastropathy in chil-
dren is unknown, it seems to be increasing, especially in
children with chronic arthritis treated with NSAIDs. Case
reports have demonstrated gastric ulceration from low-dose
ibuprofen in children, even after just 1 or 2 doses [23].
A recent study from Taiwan by Shu-Ching et al. [14]
aimed to assess the etiology, clinical, and histological char-
acteristics and treatment of PUD in children. From 1234
endoscopic examinations, 5.4% of children presented gastric
ulcer (GU) or duodenal ulcer (DU): 47.7% of these children
had HP infection and 16.5% had previous use of NSAIDs.
Non-HP, non-NSAID PUD was found in 35.8% of patients.
Children with HP-related PUD had a signiﬁcantly higher
mean age, antral chronic inﬂammatory score, rate of familial
PUD, and presence of DU and nodular gastritis than those
with NSAID-related PUD and with non-HP, non-NSAID
PUD. In contrast, children with NSAID-related PUD had
a higher rate of upper gastrointestinal bleeding, associated
with acute febrile disease, than those with HP-related and
non-HP, non-NSAID PUD. All but two patients with non-
HP, non-NSAID PUD were disease-free after HP eradication
and proton pump inhibitor treatment for 1-2 months. These
data from Taiwan concluded that in children, HP-related
PUD is associated with familial peptic ulcer and the presence
of DU. Short-term NSAID use is highly correlated with GU.
Another study by Egbaria et al. from Israel [17], where
children have a high prevalence and early acquisition of HP
and have easy access to pediatric gastroenterologists and
endoscopy, aimed to describe the prevalence and character-
istics of PUD in this population. This retrospective study
was conducted on 651 diagnostic endoscopies performed
over the time period January 2003–May 2006. PUD was
regarded as erosive gastritis/duodenitis or ulcer in either the
stomach or duodenum. HP status was assessed using rapid
urease test and gastric biopsies. PUD was detected in 22.5%
patients (ulcers 6.8%, erosions 15.7%). HP was positive in
66.3% of patients and appeared to be common after the
age of 10 years, with gastric PUD presenting much earlier
than duodenal disease. Most of the HP PUD were idiopathic
and improved symptomatically on PPI treatment. 43% of
patients with PUD were either immigrants from the former
Soviet Union or of Israeli Arab origin. In conclusion, PUD
appeared to be common in the selected population with
a relatively high incidence of gastric PUD. Non-HP PUDUlcers 5
comprised approximately a third of all PUD, and it was
mostly idiopathic and appeared earlier than HP associated
PUD.
A Spanish work by Velayos et al. [24]i n v e s t i g a t e d
the accuracy of the urea breath test (UBT) performed
immediately after emergency endoscopy in peptic ulcer
bleeding (PUB). Clinical and epidemiological factors were
moreover analyzed in order to study their inﬂuence on the
accuracy of the early UBT. Early UBT was collected from
the 74 patients included. In 71.6% of the patients, a delayed
UBT was obtained. Comparing concordance between the
two tests, an accuracy of 83% for the early UBT was
attested. Sensibility and speciﬁcity were 86.36 and 66%,
respectively, with a positive predictive value of 92.68% and
negative predictive value of 50% (Kappa index = 0.468;
P = 0.0005; CI: 95%). No inﬂuence of epidemiological
factors, clinical presentation, drugs, times to gastroscopy,
Forrest classiﬁcation, endoscopic therapy, haemoglobin, and
urea levels was attested over the accuracy of early UBT.
Considering the low negative predictive value for early UBT,
a delayed test is mandatory for all negative cases.
As t u d yf r o mS a u d iA r a b i ab yE lM o u z a na n dA b d u l l a h
[18] aimed to investigate the epidemiology and pattern
of the PUD condition in Saudi Arabia. Over a period of
10 years (from 1993 to 2002), 24 (5%) children out of
521 who presented with upper gastrointestinal tract symp-
toms were diagnosed by endoscopy to have PUD. The
most common presentation was chronic abdominal pain
(63%), followed by vomiting associated with abdominal
pain in 4%. Hematemesis and melena occurred in 13% and
8%, respectively. There were 20 duodenal (92%) and four
gastric ulcers. Histopathology results of antral biopsies all
detected antral gastritis, with detection of HP in 87% of
the specimens. The study concludes that in Saudi children,
peptic ulcer is a rare cause of upper GI symptoms, it is
mostly observed in boys and often associated with HP antral
gastritis.
Among non-HP non-NSAID-related PUD, portal hyper-
tension has been demonstrated to increase the risk for
duodenal ulcer in adults. A case-control study from Taipei by
Hung et al. [25] investigated the prevalence and characteris-
tics of DU in 80 children with portal hypertension enrolled
from January 1997 to December 2001. At upper-GI endo-
scopic evaluation, the prevalence of DU was signiﬁcantly
higher in children with portal hypertension than in children
with digestive symptoms only (P = 0.017). DU was more
common and appeared earlier in children with a history of
variceal bleeding. The presence of DU was independent of
the severity of liver disease, HP infection, and serum gastrin
level.Theauthorsconcludedandsuggestedtoscreenpatients
with gastrointestinal bleeding for DU even in the presence of
esophageal varices.
A connection between celiac disease (CD) and non-HP
non-NSAID-related PUD was attested by the experience of
Levine et al. from Israel [26], who retrospectively reviewed
all the endoscopies performed for children and young adults
diagnosedwithCDbetweenJanuary2004andOctober2008.
Twelve percent (males 52%, females 48%) of 240 enrolled
patientswithdiagnosisofCDhadanendoscopicdiagnosisof
PUD. 79% of the PUD patients were HP negative. Duodenal
PD was noted in 76% of CD patients, and 73% were HP
negative. Gastric PD was noted in 28% of CD patients, and
87% were HP negative. The PUD group was signiﬁcantly
older at diagnosis (P<0.001) compared to the whole CD
group. The authors concluded that PUD is not uncommon
in the presentation of CD and is more likely to be found
in the second decade of life. CD should be included in the
diﬀerential diagnosis of patients with non-HP PUD, and
routine CD serology and small bowel biopsy in patients with
unexplained PUD should therefore be performed.
An American study by Sarkar et al. [27] analyzed the
complications in patients after intestinal transplantation
including the occurrence of ulcers in the native or trans-
planted gastrointestinal tract. Among 112 patients with
intestinal transplantation, ulcer formation was endoscopi-
cally detected in 11 patients. At the histological examination,
the most common changes in the ulcers were compatible
with posttransplant lymphoproliferative disorder (PTLD),
acute rejection, and viral infections. Some patients were
treated for rejection based on the changes within the mucosa
outside the ulcer bed, and they responded with resolution
of the ulcers. These ﬁndings demonstrate that PTLD and
acute rejection are the most common causes of chronic
ulcer formation in patients with intestinal transplantation
and conﬁrm the importance of collecting biopsy samples
simultaneously from both the ulcer edge and intervening
mucosa.
An Italian case report by Lionetti et al. [28] highlights
PUD as a possible threatening GI complication in children
with neuroﬁbromatosis type 1 (NF1) and primary ciliary
dyskinesia(PCD).Theuppergastrointestinalendoscopyper-
formedrevealedthepresenceofmultiplegastriculcerswhich
scarred after the long-term administration of a proton pump
inhibitor, but recurred after the suspension. Laboratory and
imaging studies excluded Zollinger-Ellison syndrome and
other known causes of PUD, suggesting a potential role of
NF1 itself and PCD in developing of recurrent PUD. As an
early diagnosis of PUD is vital for patient survival, gastric
protection before complications arise is to be considered for
patients with diagnosis of NF1 and/or PCD.
2.2.EvidencesonAvailableTreatmentsforPepticUlcerDisease.
WhentheunderlyingcauseofPUDisaddressed,theprogno-
sis is excellent [29]. With regard to NSAID related ulcers, the
incidence of perforation is approximately 0.3% per patient
year, and the incidence of obstruction is approximately 0.1%
perpatientyear.Combiningbothduodenalulcersandgastric
ulcers, the rate of any complication in all groups combined is
approximately1-2%perulcerperyear.Themortalityratefor
PUD is approximately 1 death per 100.000 cases.
HP related ulcers are treated with a course of antibiotics
to eradicate the bacterium from the GI tract, as well as with
drugs to reduce stomach acid and protect the stomach lining
[6].
In 2011 the European and North American Societies
of Pediatric Gastroenterology Hepatology and Nutrition
(ESPGHAN and NASPGHAN) emitted evidence-based
guidelines for managing HP in children [12]. For children6 Ulcers
with HP infection without PUD, treatment should be con-
sidered by the clinician evaluating the potential advantages
andtheriskfactorsofadevelopedchronicinfectionwithbad
consequences.
The ﬁrst line recommended therapies are [6–12]a s
follows:
(i) standard triple therapy with proton pump inhibitor-
PPI (1-2mg/kg/day), ampicillin-AMPC (50mg/kg/
day), clarithromicin-CAM (20mg/kg/day), or met-
ronidazole-MNZ (20mg/kg/day);
(ii) bismuth-based quadruple therapy: bismuth subsal-
icylate (8mg/kg/day), AMPC (50mg/kg/day), and
MNZ (20mg/kg/day);
(iii) sequential therapy: PPI (1-2mg/kg/day), AMPC
(50mg/kg/day) for 5 days, then PPI (1-2mg/kg/day),
CAM (20mg/kg/day), and MNZ (20mg/kg/day) for
5d a y s .
As for adults, an antibiotic susceptibility test should be
performed whenever a high resistance rate (>20%) in the
area is known. Once treatment is completed, a non invasive
test should be done to ensure eradication [12].
NSAIDs related ulcers are treated by stopping the
causative medications, and by administering drugs that
promote healing of the stomach lining.
Stress ulcers, erosions of the stomach and duodenum,
and upper GI bleeding are well-known complications of
critical illness in children admitted to pediatric intensive
care units. Severe illness and a decreased gastric pH are in
fact related to an increased risk of gastric ulceration and
haemorrhage.
Prophylactic regimens with PPIs have been shown to
dramatically reduce the risk of gastric and duodenal ulcers
[30]. Maintenance therapy with antisecretory medications
(i.e., H2-blockers, PPIs) for 1 year is indicated in high-risk
patients.
AsystematicreviewbyReveizetal.[31]aimedtoidentify
and evaluate the quality of evidence supporting prophylactic
use of treatments for stress ulcers and upper gastrointestinal
bleeding. When pooling two randomized controlled trials,
treatment was signiﬁcantly more eﬀective in preventing
upper gastrointestinal bleeding (macroscopic or important
bleeding) compared with no treatment. No signiﬁcant
diﬀerence was seen in death rates among the two groups.
The rate of pneumonia was not signiﬁcantly diﬀerent
when comparing treatment and no treatment in one study.
When comparing ranitidine with no treatment, signiﬁcant
diﬀerences were found in the proportion of mechanically
ventilated children with normal gastric mucosal endoscopic
ﬁndings by histological specimens.
No signiﬁcant diﬀerences were found when comparing
diﬀerent drugs (omeprazole, ranitidine, sucralfate, famoti-
dine, and amalgate), doses, or regimens for main outcomes
(deaths, endoscopic ﬁndings of erosion or ulcers, upper
gastrointestinal bleeding, or pneumonia).
A multicenter, prospective, cross-sectional observational
study by Araujo et al. from Brazil [32] evaluated the use
of stress ulcer prophylaxis in patients admitted to ﬁve
pediatric intensive care units (PICUs) in Porto Alegre.
Medical records of 398 patients (57% males) admitted from
April 2006 to February 2007 were reviewed. The mean
age was 16 months (IQR 4–65) and respiratory illness
was the main reason for admission (32.7%). Most patients
received stress ulcer prophylaxis (77.5%). Ranitidine was
the most commonly used drug (84.5%). Evidence of minor
gastrointestinal bleeding was found in 3% of patients; none
had clinically signiﬁcant bleeds.The authors concluded that
administration of stress ulcer prophylaxis is a common
practice in the participating PICUs, with ranitidine the
most commonly used drug. Among the various rationales
provided, mechanical ventilation and informal routine use
were the most prevalent.
Another Chinese study by Wu [33]i n v e s t i g a t e da n d
proved the eﬃcacy and safety of famotidine treatment for
stress ulcers in 54 neonates with stress ulcers enrolled from
2001 to 2006.
After24hoursoffamotidinetreatment,hematemesisand
vomiting ceased in 96.3% of patients. Clinical symptoms
disappeared in all patients 48hrs after famotidine treatment.
Gastric pH value increased after famotidine treatment from
2.07 ± 0.22 (before treatment) to 5.01–5.15 (P<0.01).
Famotidine treatment did not lead to abnormal respiration,
heart rate, and blood pressure. Loss of appetite, nausea,
vomiting, diarrhoea, constipation, and rashes were not seen
in this study whereas signiﬁcant diﬀerences in white cell
count, platelet count, and hepatic enzyme levels before and
after famotidine treatment were attested.
A prospective study from the US by Toﬁl et al. [34]
aimedtoassessgastricpHin48criticallyillpediatricpatients
(median age 7 years, 5 months; range 1 month to 19 years)
with a gastric tube in place, receiving intravenous stress ulcer
medication (either ranitidine or a proton pump inhibitor)
and no enteral nutrition. All patients were intubated. Ten
percent of 28 trough pH measurements in the twice daily
proton pump inhibitor group were more acidic than pH 4
versus 40% of 60 in the ranitidine group, and 40% of 56
in the once daily proton pump inhibitor group (P = 0.02).
Four percent of 27 peak pH measurements in the twice daily
proton pump inhibitor group were more acidic than pH 4
versus 20% of 61 in the ranitidine group, and 16% of 56
in the once daily proton pump inhibitor group (P = 0.12).
Three patients (6%; 95% CI, 0.51%–16%) developed upper
gastrointestinal bleeding, and 4 patients (8%; 95% CI, 0%–
13%) developed ventilator-acquired pneumonia. This study
attests that many critically ill pediatric patients receiving
stress ulcer prophylaxis have a trough or peak gastric pH
more acidic than 4.
EmergencyGIendoscopyforupper-GIhemorrhageleads
to identiﬁcation of the bleeding lesion in more than 80%
of cases [35]. The endoscopic assessment should ideally
be performed within 6–12 hours after stabilization of the
patient. In pediatric patients, gastric and duodenal ulcers
are the main indications for endoscopic treatment of non-
variceal GI haemorrhage [36].
Endoscopically visible vessels are usually associated with
an organizing clot in the artery close to the ulcer base [35].
Upper GI tract haemorrhage can be endoscopically treatedUlcers 7
using either thermal methods (including laser, heater probe,
monopolar or multipolar probes, and plasma argon coagu-
lation) or nonthermal methods (injection of suitable vaso-
constrictive or sclerosing agents). Both methods appear to be
equally eﬀective but injection is generally preferred because
it is cheaper and can be done using a small endoscope [35].
The agents used for injection therapy include dilute
epinephrine (1:10.000), sclerosants, thrombin, and ﬁbrin
sealant [35].
Injection therapy with dilute epinephrine reduces the
need for surgical intervention and blood transfusion [35].
Submucosal injection of epinephrine causes local vasocon-
striction, platelet aggregation, and also volume tampon-
ade. In actively bleeding ulcers, this promptly induces a
haemostasis preceded by mucosal oedema and blanching.
Since epinephrine does not induce vessel thrombosis, bleed-
ing may recur [35].
Sclerosants such as polidocanol and sodium tetradecyl
sulfate cause tissue necrosis and ulceration: they are used in
adults whereas they are not generally used in children, given
some reports of fatal gastric necrosis [35].
Thrombin and ﬁbrin sealant injections are used in adults
but, since the high viscosity of ﬁbrinogen requires a very
wide endoscopic channel, the technique is not performed on
children [36].
Metallic clips are also available for endoscopic haemosta-
sis of bleeding ulcers, even though the procedure can be
technically diﬃcult for ulcers localised in the posterior wall
oftheduodenalbulbaswellasforthoselocalisedinthelesser
curvature [35].
Thermal devices using contact, include heater probes
which are available in two sizes, even though only the smaller
type can be used in children aging less than 12 years of age
[35].
Thermal devices which do not require contact include
argon plasma coagulation which is eﬀective for both oozing
and pulsatile arterial bleeding. The technique is safe provok-
ing superﬁcial eﬀects only, with a low risk of perforation;
it consists, in children, in the use of a 2.3mm diameter
ﬂexible delivery catheter ﬁlled with argon gas which is passed
through the operating channel and the tip of the probe
is placed closed to the lesion but without touching it; a
coagulative gas ﬂow is then activated [35].
The indications for urgent surgery include failure
to achieve haemostasis endoscopically, recurrent bleeding
despite endoscopic attempts at achieving haemostasis, and
perforation.
A retrospective and prospective hospital-based study
in Ghana by Dakubo et al. [36] aimed to determine the
epidemiology of and deﬁne the morbidity and mortality
factors following emergency surgery for 326 patients (range
4–87 years) with perforated PUD. The incidence of PUD in
this population was of 5%, and overall accounted for 4.6% of
acute abdomen. Comorbid conditions were present in 18.2%
of cases. Ulcerogenic substance intake was in 67% patients.
46.2% patients reported to hospital within 24 hours of per-
foration. Simple closure with omental patch was performed
in 94.3%, truncal vagotomy and drainage in 3.2%, and
Billroth II partial gastrectomy in seven 2.2%. Postoperative
complications occurred in 19%; overall mortality was 11%.
This study concluded that perforated PUD is emerging as
a frequent cause of acute abdomen and aﬀects the youth
commonly. A logistic regression analysis of data showed
that age of 60 years and above, duration of perforation for
more than 24 hours before admission, alcohol intake and
resectional surgery were the variables that showed statistical
signiﬁcance in predicting postoperative morbidity and/or
mortality.
Another study by Wong et al. from Hong Kong [37]
aimed to determine the eﬃcacy, safety, and outcome of
132 children and adolescents undergoing minimally invasive
treatment of bleeding and perforation complicating PUD,
within the time period from of January 1999 to February
2006. Among 30 children with signiﬁcant endoscopic stigma
of recent haemorrhage, primary endoscopic hemostasis
was achieved in all cases except one. Seventeen patients
with perforation underwent laparoscopic patch repair. Four
patients were converted to open repair because of technical
diﬃculty and the large size of the ulcer. All patients had
a course of proton pump inhibitors postoperatively. Ninety
percent of patients had HP infestation and were treated
with triple therapy; two patients defaulted triple therapy
and presented later with recurrent ulcer bleeding. All others
remained asymptomatic on followup (average 32.6 months).
Thisstudyconcludedthatendoscopichemostasisofbleeding
peptic ulcer is eﬀective and safe in children. With stringent
criteria, laparoscopic patch repair of perforation can be
applied safely to most pediatric patients. Eradication of HP
and subsequent antiulcer medication are integral in the
management of complicated PUD.
3. Conclusions
PUD in children is reported worldwide with an estimated
frequency of 8.1% in Europe and of 17.4% in the US,
thus remaining relatively rare as compared with adults.
PUD mainly occurs in the second decade of life and the
most common identiﬁed causes in the pediatric age are
HP infection and the use of NSAIDs. Other stressful events
(i.e., shock, sepsis, burnings, major trauma, intracranial
hypertension, surgical procedures, and chronic diseases) can
provoke acute gastric ulcers, also in children. Associations
of PUD with celiac disease, portal hypertension, intestinal
transplantation, and neuroﬁbromatosis are described as well
in the pediatric age. An hereditary component is supported
by the evidence that more than 20% of patients have a
familyhistoryofduodenalulcers;increasedbasalacidoutput
and maximal acid output and accelerated gastric emptying
are often observed within this subgroup of patients. Alarm
symptoms supporting the suspect of GI bleeding or ulcer
perforation include sudden, sharp abdominal pain, black or
bloody stools, and bloody or coﬀee-like vomits. Diagnostic
examinations is based on rapid urease tests and stool tests
for HP detection, and upper-gastrointestinal (GI) tract
endoscopy.
When the underlying cause of PUD is addressed, the
prognosis is excellent; combining both duodenal ulcers and8 Ulcers
gastric ulcers, the rate of any complication in all groups
combined is approximately 1-2% per ulcer per year in
the general population. The mortality rate for PUD is
approximately 1 death per 100.000 cases.
HP related ulcers in the children are treated according to
the2011 EvidenceBasedGuidelines emitted bytheEuropean
and North American Societies of Pediatric Gastroenterology
Hepatology and Nutrition (ESPGHAN and NASPGHAN)
emitted evidence-based guidelines for managing HP in chil-
dren.Theﬁrstlinerecommendedthattherapiescomprehend
the standard triple therapy, the bismuth-based quadruple
therapy, and the sequential therapy.
NSAIDs related ulcers are treated by stopping the
causative medications and by administering drugs that
promote healing of the stomach lining.
Stress ulcers, erosions of the stomach and duodenum,
and upper-GI bleeding are well-known complications of
critical illness in children admitted to pediatric intensive care
units. Adequate prophylactic regimens have been shown to
dramatically reduce the risk of gastric and duodenal ulcers
and should therefore be routinely administered within this
subgroup of patients.
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